Healthcare / BiotechnologyNasdaqGM
$6.37
-0.09 (-1.32%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-16.2M · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$383M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-67.4%
↓Gross Margin
94.0%
↑Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
+27.3%
FCF CAGR
—
FCF margin
-51.1%
FCF / Net income
0.50x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $216.1M · net income $-220.5M · FCF $-110.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $216.1M | $216.1M | $198.8M | $192.6M | $254.4M | $268.7M | $248.2M | $227.2M | $193.1M | $165.1M | $146.0M | $109.9M | $50.2M | $33.9M | $32.7M | $31.3M | $35.7M | $4.5M |
| Net Income | $-220.5M | $-220.5M | $-18.9M | $2.5M | $6.3M | $33.2M | $23.3M | $115.6M | $25.2M | $-15.6M | $-18.0M | $-39.9M | $20.2M | $-21.1M | $-28.6M | $-9.8M | $7.2M | $-35.9M |
| EBITDA | $-139.3M | $-139.3M | $-30.9M | $-9.6M | $9.1M | — | — | — | — | — | — | — | $20.6M | $-20.8M | $-28.5M | $-10.2M | $9.2M | $-35.5M |
| EPS | -3.74 | -3.74 | -0.33 | 0.04 | 0.11 | 0.58 | 0.42 | 2.11 | 0.48 | -0.35 | -0.41 | -0.94 | 0.55 | -0.69 | -1.01 | -0.35 | 0.25 | -1.33 |
| Gross Margin | 94.0% | 94.0% | 94.3% | 92.3% | 90.5% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -70.0% | -70.0% | -20.5% | -7.2% | 2.5% | 15.7% | 11.0% | 10.0% | 11.3% | -10.2% | -12.7% | -36.6% | 40.0% | -62.6% | -89.2% | -34.2% | 24.8% | -790.4% |
| Net Margin | -102.0% | -102.0% | -9.5% | 1.3% | 2.5% | 12.3% | 9.4% | 50.9% | 13.1% | -9.4% | -12.3% | -36.3% | 40.2% | -62.1% | -87.4% | -31.3% | 20.1% | -788.5% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 0.04 | 0.04 | 0.02 | 0.02 | 0.02 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 2.16 | 2.16 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $-110.4M | $-110.4M | $-16.2M | $12.4M | $31.3M | $63.7M | $50.0M | $44.9M | $29.6M | $-3.6M | — | — | — | $-39.8M | $-46.9M | $-28.7M | — | — |
| Returns | ||||||||||||||||||
| ROE | -67.4% | -67.4% | -3.5% | 0.5% | 1.2% | 6.6% | 5.1% | 28.1% | 9.2% | -11.8% | -13.7% | -30.0% | 12.6% | -47.7% | -288.9% | -29.3% | 19.1% | -155.7% |
| Valuation | ||||||||||||||||||
| P/E | — | — | — | 104.75 | 67.45 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | — | — | — | — | 32.99 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 1.15 | 1.15 | 0.52 | 0.44 | 0.80 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | 8.7% | 8.7% | 3.2% | -24.3% | — | 8.3% | 9.2% | 17.6% | 17.0% | 13.1% | 32.8% | 119.2% | 48.0% | 3.5% | 4.7% | -12.4% | 685.2% | — |
| EPS Growth | -1033.3% | -1033.3% | -925.0% | -63.6% | — | 38.1% | -80.1% | 339.6% | 237.1% | 14.6% | 56.4% | -270.9% | 179.7% | 31.7% | -188.6% | -240.0% | 118.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+46.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.33 → -3.74
Residual
+46.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.